New York State Common Retirement Fund’s Corvus Pharmaceuticals CRVS Stock Holding History

New York State Common Retirement Fund’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$375K	Buy	25,100 +7,000	+39%	+$97.1K	﹤0.01%	2117
2026 Q1	$265K	Sell	18,100 -700	-4%	-$11.2K	﹤0.01%	2128
2025 Q4	$145K	Hold	18,800	–	–	﹤0.01%	2435
2025 Q3	$139K	Sell	18,800 -5,000	-21%	-$25.6K	﹤0.01%	2459
2025 Q2	$95.2K	Buy	+23,800	New	+$86.6K	﹤0.01%	2714
2019 Q2	–	Sell	-9,500	Closed	-$38K	–	3257
2019 Q1	$38K	Hold	9,500	–	–	﹤0.01%	3098
2018 Q4	$35K	Hold	9,500	–	–	﹤0.01%	3120
2018 Q3	$82K	Hold	9,500	–	–	﹤0.01%	3072
2018 Q2	$104K	Hold	9,500	–	–	﹤0.01%	3077
2018 Q1	$110K	Hold	9,500	–	–	﹤0.01%	2930
2017 Q4	$98K	Hold	9,500	–	–	﹤0.01%	2977
2017 Q3	$151K	Hold	9,500	–	–	﹤0.01%	2906
2017 Q2	$115K	Buy	9,500 +9,099	+2,269%	+$97.1K	﹤0.01%	3056
2017 Q1	$8K	Buy	401 +1	+0.3%	+$16	﹤0.01%	3130
2016 Q4	$6K	Hold	400	–	–	﹤0.01%	3116
2016 Q3	$7K	Sell	400 -7,100	-95%	-$102K	﹤0.01%	3127
2016 Q2	$107K	Buy	+7,500	New	+$101K	﹤0.01%	2964

Other funds holding CRVS

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

SAM

SEB Asset Management Stockholm $26.6B AUM

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

FMI

F/M Investments Washington, District of Columbia $1.97B AUM 30.33% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

TowerView LLC New York $152M AUM 20.28% 1-Year Est. Return

New York State Common Retirement Fund's CRVS Position: Q2 2026 in Review

New York State Common Retirement Fund increased its Corvus Pharmaceuticals (CRVS) stake by 39% in Q2 2026, buying an estimated $97.1K and bringing the position to 25,100 shares worth $375K. The position accounts for ﹤0.01% of the portfolio, ranked #2117.

New York State Common Retirement Fund first reported a position in CRVS in Q2 2016 and has held it in 17 quarters since. 43 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

New York State Common Retirement Fund held 25,100 shares of Corvus Pharmaceuticals worth $375K as of Q2 2026.
New York State Common Retirement Fund bought 7,000 Corvus Pharmaceuticals shares in Q2 2026, an estimated $97.1K.
Corvus Pharmaceuticals made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #2117 holding.
New York State Common Retirement Fund first reported a position in Corvus Pharmaceuticals in Q2 2016 and has held it in 17 quarters since.
43 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.